A new inhalation treatment for lung diseases caused by mucus buildup
A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases
This study is testing a new inhaler solution that combines two ingredients to help people with lung diseases like COPD, asthma, and cystic fibrosis breathe better by clearing out mucus that blocks their airways.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Parion Sciences, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10918480 on NIH RePORTER |
What this research studies
This research focuses on developing a novel inhalation solution that combines a new ENaC blocker with an osmolyte to help patients suffering from muco-obstructive lung diseases like COPD, asthma, and cystic fibrosis. The approach aims to rehydrate and clear mucus plugs that contribute to airway obstruction, which has been shown to persist in patients for extended periods. By utilizing a combination of laboratory studies and clinical trials, the research seeks to establish a new therapeutic option for improving lung function and quality of life for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with muco-obstructive lung diseases such as COPD, asthma, cystic fibrosis, or primary ciliary dyskinesia.
Not a fit: Patients with lung diseases not primarily associated with mucus obstruction or those who do not respond to inhalation therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that effectively clears mucus from the lungs, improving breathing and overall health for patients with chronic lung conditions.
How similar studies have performed: Previous research has shown promise with similar therapeutic approaches, particularly in the treatment of primary ciliary dyskinesia, indicating potential for success in this novel application.
Where this research is happening
Durham, United States
- Parion Sciences, INC. — Durham, United States (Active)
Researchers
- Principal investigator: Donn, Karl H — Parion Sciences, INC.
- Study coordinator: Donn, Karl H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.